Pharmacogenomics of Coronary Artery Response to Intravenous Gamma Globulin in Kawasaki Disease - Shrestha, Sadeep; Wiener, Howard W; Chowdhury, Sabrina; Kajimoto, Hidemi; Srinivasasainagendra, Vinodh; Mamaeva, Olga A; Brahmbhatt, Ujval N; Ledee, Dolena; Lau, Yung; Padilla, Luz A; Chen, Jake; Dahdah, Nagib; et al. (medRxiv, 2024)
Background Kawasaki disease (KD) is a multisystem inflammatory illness of infants and young children that can result in acute vasculitis. The pathological walls of afflicted coronary arteries show propensity for forming thrombosis and aneurysms. The mechanism of coronary artery aneurysms (CAA) despite intravenous gamma globulin (IVIG) treatment is not known.Methods We performed a Whole Genome Sequencing (WGS) association analysis in a racially diverse cohort of KD patients treated with IVIG, both using AHA guidelines. We defined coronary aneurysm (CAA) (N = 234) as coronary z>2.5 and large coronary aneurysm (CAA/L) (N = 92) as z>5.0. We conducted logistic regression models to examine the association of genetic variants with CAA/L during acute KD and with persistence >6 weeks using an additive model between cases and 238 controls with no CAA. We adjusted for age, gender and three principal components of genetic ancestry. We performed functional mapping and annotation (FUMA) analysis and further assessed the predictive risk score of genomic risk loci using the area under the receiver operating characteristic curve (AUC).Results The top significant variants associated with CAA/L were in the intergenic regions (rs62154092 p<6.32E-08 most significant). Variants in SMAT4, LOC100127, PTPRD, TCAF2 and KLRC2 were the most significant non-intergenic SNPs. FUMA identified 12 genomic risk loci with eQTL or chromatin interactions mapped to 48 genes. Of these NDUFA5 has been implicated in KD CAA and MICU and ZMAT4 has potential functional implications. Genetic risk score using these 12 genomic risk loci yielded an AUC of 0.86.Conclusions This pharmacogenomics study provides insights into the pathogenesis of CAA/L in IVIG-treated KD patients. We have identified multiple novel SNPs associated with CAA/L and related genes with potential functional implications. The study shows that genomics can help define the cause of CAA/L to guide management and improve risk stratification of KD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Institutes of Health grant NHLBI-1R01HL146130.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The parent cohort/study and this genomic study conformed to the procedures for informed consent (parental permission) approved by institutional review boards at Centre Hospitalier Universitaire Ste-Justine Universite de Montreal, Children Hospital of Seattle, and the University of Alabama at Birmingham.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data have been deposited with links to BioProject accession number PRJNA1055092 in the NCBI BioProject database and will available per the repository guidelines (https://www.ncbi.nlm.nih.gov/bioproject/).AUCArea Under the CurveCAACoronary Artery AneurysmCAA/LLarge Coronary Artery AneurysmCADDCombined Annotation-Dependent DepletionDNADeoxyribonucleic AcideQTLExpression Quantitative Trait LociFUMAFunctional Mapping and AnnotationGATKGenome Analysis Tool KitGRSGene Risk ScoreGTExGenotype Tissue ExpressionHWEHardy-Weinberg equilibriumIVIGIntravenous ImmunoglobulinKDKawasaki DiseaseLADLeft Anterior Descending ArteryLDLinkage DisequilibriumLMCALeft Main Coronary ArteryMAFMinor Allele FrequencyPCAPrincipal Components AnalysisQCQuality ControlQQQuantile-quantileRCARight Coronary ArteryROCReceiver Operating CharacteristicSNPSingle Nucleotide PolymorphismWGSWhole Genome Sequencing